{"id":"ibandronate-bondronat","safety":{"commonSideEffects":[{"rate":null,"effect":"Osteonecrosis of the jaw"},{"rate":null,"effect":"Atypical femoral fractures"},{"rate":null,"effect":"Musculoskeletal pain"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Renal impairment"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Bisphosphonates like ibandronate are taken up by osteoclasts during bone resorption and inhibit the mevalonate pathway, leading to osteoclast apoptosis and reduced bone turnover. This mechanism makes it effective for conditions characterized by excessive bone loss, including osteoporosis and bone metastases in cancer patients.","oneSentence":"Ibandronate is a bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite in bone and blocking farnesyl pyrophosphate synthase in the mevalonate pathway.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:47:57.740Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Bone metastases in breast cancer"},{"name":"Osteoporosis prevention and treatment"},{"name":"Hypercalcemia of malignancy"}]},"trialDetails":[{"nctId":"NCT07406685","phase":"PHASE4","title":"The Comparison of Ibandronate and Zoledronic Acid After Denosumab Discontinuation","status":"NOT_YET_RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2026-03-17","conditions":"Postmenopausal Osteoporosis, Postmenopausal Osteopenia, Primary Osteoporosis","enrollment":52},{"nctId":"NCT07242612","phase":"NA","title":"Bone Turnover Markers and Treatment Efficacy in Postmenopausal Osteoporosis","status":"RECRUITING","sponsor":"Khyber Medical University Peshawar","startDate":"2025-10-01","conditions":"Osteoporosis, Osteoporosis, Postmenopausal","enrollment":40},{"nctId":"NCT07043608","phase":"PHASE2","title":"Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases","status":"NOT_YET_RECRUITING","sponsor":"Kelly Fitzgerald, MD","startDate":"2025-09-30","conditions":"Clear Cell Renal Cell Cancer (ccRCC), Clear Cell Renal Carcinoma, Clear Cell Renal Cell Carcinoma Metastatic","enrollment":20},{"nctId":"NCT02520362","phase":"","title":"Denosumab Safety Assessment in Multiple Observational Databases","status":"COMPLETED","sponsor":"Amgen","startDate":"2010-05-31","conditions":"Osteoporosis","enrollment":517991},{"nctId":"NCT04321837","phase":"PHASE2","title":"Coral Calcium's Effect on Bone Density in Postmenopausal Women With and Without Ibandronate","status":"COMPLETED","sponsor":"Columbia University","startDate":"2020-02-05","conditions":"Osteoporosis, Postmenopausal","enrollment":60},{"nctId":"NCT02635997","phase":"","title":"Antiresorptive Effects of a 6-m Treatment Course With Ibandronate Plus Supplementation of Vitamine D and Calcium in Central America","status":"COMPLETED","sponsor":"Pontifical Catholic University of Argentina","startDate":"2013-01","conditions":"Osteoporosis","enrollment":425},{"nctId":"NCT06022237","phase":"NA","title":"Efficacy and Safety of Oral Ibandronate in Patients of Liver Cirrhosis With Hepatic Osteodystrophy.","status":"UNKNOWN","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2023-09-01","conditions":"Hepatic Osteodystrophy, Liver Cirrhosis","enrollment":80},{"nctId":"NCT05366621","phase":"","title":"Post-fracture Medication and Mortality","status":"COMPLETED","sponsor":"National Cheng-Kung University Hospital","startDate":"2020-11-01","conditions":"Osteoporosis, Osteoporosis Fracture, Drug Therapy","enrollment":216155},{"nctId":"NCT01875458","phase":"","title":"Biomarker Identification in Orthopaedic & Oral Maxillofacial Surgery Subjects to Identify Risks of Bisphosphonate Use","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2012-04-13","conditions":"Osteoporosis, With or Without Treatment, Bisphosphonate Treatment, Atypical Femur Fracture","enrollment":314},{"nctId":"NCT05266261","phase":"NA","title":"Use of Ibandronate in Diabetic Patients","status":"COMPLETED","sponsor":"Yeouido St. Mary's Hospital","startDate":"2018-10-01","conditions":"Osteoporosis, Postmenopausal, Type 2 Diabetes","enrollment":121},{"nctId":"NCT01077817","phase":"","title":"Observational Study of Incidence Rates of Esophageal Cancer in Women Taking Medications for the Prevention or Treatment of Osteoporosis (MK-0217A-352)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2010-02-26","conditions":"Esophageal Cancer, Squamous Cell Carcinoma, Adenocarcinoma","enrollment":684815},{"nctId":"NCT00092053","phase":"PHASE3","title":"Study of Investigational Drug in Osteoporosis (MK-0217-908)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2004-12","conditions":"Postmenopausal Osteoporosis","enrollment":203},{"nctId":"NCT03186131","phase":"PHASE2","title":"Efficacy of Oral Ibandronate in Osteoporosis","status":"UNKNOWN","sponsor":"Shinshu University","startDate":"2017-10-12","conditions":"Osteoporosis","enrollment":100},{"nctId":"NCT02156999","phase":"PHASE4","title":"Changes of Bone Turnover Markers and Bone Mineral Density After Osteoporosis Treatment","status":"UNKNOWN","sponsor":"Shinshu University","startDate":"2014-06","conditions":"Osteoporosis","enrollment":100},{"nctId":"NCT00127205","phase":"PHASE3","title":"S0307 Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer.","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"2005-07","conditions":"Breast Cancer","enrollment":6097},{"nctId":"NCT02616744","phase":"PHASE2","title":"Study of Oral Bisphosphonate for Osteopenic Women Treated With Adjuvant Aromatase Inhibitors","status":"COMPLETED","sponsor":"Azienda Ospedaliero-Universitaria Careggi","startDate":"2011-01","conditions":"Breast Cancer","enrollment":171},{"nctId":"NCT00662077","phase":"PHASE4","title":"Study Of The Efficacy And Security Of Ibandronate For Osteoporosis Treatment In A HIV-Infected Patients Cohort","status":"WITHDRAWN","sponsor":"Germans Trias i Pujol Hospital","startDate":"","conditions":"HIV Infections","enrollment":""},{"nctId":"NCT01406613","phase":"","title":"Resolution of Effect of Bisphosphonates on Bone in Postmenopausal Osteoporosis","status":"COMPLETED","sponsor":"Sheffield Teaching Hospitals NHS Foundation Trust","startDate":"2010-03","conditions":"Postmenopausal Osteoporosis","enrollment":86},{"nctId":"NCT02731040","phase":"","title":"Exome Sequencing for Atypical Femoral Fractures","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2016-04","conditions":"Atypical Femoral Fractures, Osteoporosis, Bisphosphonate Therapy","enrollment":38},{"nctId":"NCT00824993","phase":"PHASE3","title":"Prevention of Osteoporosis in Bone Marrow Transplantation (BMT) Patients","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2008-12-09","conditions":"Hematological Malignancies","enrollment":78},{"nctId":"NCT00405392","phase":"PHASE4","title":"Study To Investigate Patient Preference On Dosing In Ibandronate And Risedronate In Korean Women With Postmenopausal Osteoporosis","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-03-22","conditions":"Osteoporosis, Postmenopausal","enrollment":365},{"nctId":"NCT00048061","phase":"PHASE3","title":"MOBILE Study - A Study of Bonviva (Ibandronate) Regimens in Women With Post-Menopausal Osteoporosis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2002-04","conditions":"Post Menopausal Osteoporosis","enrollment":1609},{"nctId":"NCT00666627","phase":"PHASE2","title":"Bisphosphonate Action on the Appendicular Skeleton: Evidence for Differential Effects","status":"COMPLETED","sponsor":"Sheffield Teaching Hospitals NHS Foundation Trust","startDate":"2007-04","conditions":"Post-menopausal Osteoporosis","enrollment":410},{"nctId":"NCT00099203","phase":"PHASE3","title":"A Study to Assess the Efficacy of Intravenous Bondronat (Ibandronate) in Patients With Malignant and Painful Bone Disease","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2005-07","conditions":"Pain, Bone Neoplasm, Neoplasm Metastasis","enrollment":163},{"nctId":"NCT00478270","phase":"PHASE2","title":"A Study of Loading Doses of Intravenous Bondronat (Ibandronate) in Patients With Breast Cancer and Metastatic Bone Disease.","status":"WITHDRAWN","sponsor":"Hoffmann-La Roche","startDate":"2007-06","conditions":"Pain, Bone Neoplasm, Neoplasm Metastasis","enrollment":""},{"nctId":"NCT00099177","phase":"PHASE3","title":"A Study to Assess the Efficacy of Intravenous/Oral Bondronat (Ibandronate) in Patients With Metastatic Bone Disease Experiencing Moderate to Severe Pain","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2005-08","conditions":"Pain, Bone Neoplasm, Neoplasm Metastasis","enrollment":96},{"nctId":"NCT00081653","phase":"PHASE4","title":"A Study of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis Previously Treated With Bonviva","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2004-05","conditions":"Post-Menopausal Osteoporosis","enrollment":719},{"nctId":"NCT00327990","phase":"PHASE4","title":"Evaluation Of Missed Osteoporosis Diagnoses, And Preference Between Once Monthly Ibandronate And Once Weekly Alendronate","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-04","conditions":"Osteoporosis","enrollment":300},{"nctId":"NCT02114489","phase":"PHASE3","title":"Study Comparing Ibandronate Versus Placebo in Hip Osteonecrosis","status":"TERMINATED","sponsor":"Brigitte Jolles, MD","startDate":"2014-06","conditions":"Aseptic Hip Necrosis, Hip Necrosis","enrollment":8},{"nctId":"NCT00545207","phase":"PHASE3","title":"A Study of Bonviva (Ibandronate) Once Monthly in Post-Menopausal Women With Osteopenia.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"","conditions":"Post-Menopausal Osteopenia","enrollment":150},{"nctId":"NCT00545090","phase":"PHASE4","title":"ExBonAdAsia Study: A Study of Once Monthly Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2006-08","conditions":"Post Menopausal Osteoporosis","enrollment":561},{"nctId":"NCT00148915","phase":"PHASE4","title":"A Study To Assess the Quality and Strength of Bone in Women Participants With Osteoporosis Taking Oral Ibandronate Versus Placebo","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2005-08","conditions":"Osteoporosis","enrollment":98},{"nctId":"NCT02564107","phase":"PHASE4","title":"A Study of Ibandronate (Bondronat) in Participants With Metastatic Bone Disease","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2004-11","conditions":"Pain; Bone Neoplasms; Neoplasm Metastasis","enrollment":48},{"nctId":"NCT02598453","phase":"PHASE4","title":"PRIOR Study - A Study of Ibandronate (Boniva) in Postmenopausal Women With Osteoporosis or Osteopenia","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2005-01","conditions":"Postmenopausal Osteoporosis","enrollment":545},{"nctId":"NCT02604836","phase":"PHASE4","title":"A Study of Ibandronate (Boniva) to Evaluate Satisfaction in Women With Post-Menopausal Osteoporosis or Osteopenia","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2004-06","conditions":"Postmenopausal Osteoporosis","enrollment":1711},{"nctId":"NCT02598440","phase":"PHASE4","title":"A Study of Ibandronate (Bonviva) in Patients With Post-Menopausal Osteoporosis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2004-03","conditions":"Postmenopausal Osteoporosis","enrollment":341},{"nctId":"NCT01128257","phase":"","title":"A Study of Ibandronate [Bonviva/Boniva] and Alendronate in Female Patients With Post-Menopausal Osteoporosis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2010-04","conditions":"Postmenopausal Osteoporosis","enrollment":6054},{"nctId":"NCT00493532","phase":"","title":"A Study of Quarterly Intravenous Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis.","status":"NO_LONGER_AVAILABLE","sponsor":"Hoffmann-La Roche","startDate":"2007-06","conditions":"Postmenopausal Osteoporosis","enrollment":""},{"nctId":"NCT02561039","phase":"PHASE3","title":"A Study of Ibandronate (Bondronat) in Participants With Malignant Bone Disease","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2006-12","conditions":"Pain; Bone Neoplasms; Neoplasm Metastasis","enrollment":97},{"nctId":"NCT00545909","phase":"PHASE4","title":"BEATRIS Study: A Study of Adherence to Bonviva (Ibandronate) Once Monthly in Women With Post-Menopausal Osteoporosis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2006-03","conditions":"Postmenopausal Osteoporosis","enrollment":585},{"nctId":"NCT02553850","phase":"","title":"An Observational Study in Patients With Breast Cancer and Bone Metastases Receiving Ibandronate (Bondronat)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2007-04","conditions":"Breast Cancer","enrollment":442},{"nctId":"NCT01429675","phase":"PHASE1","title":"Safety and Pharmacokinetic Characteristics of DP-R206 in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"Alvogen Korea","startDate":"2011-08","conditions":"Healthy","enrollment":105},{"nctId":"NCT01581320","phase":"PHASE3","title":"Phase III Clinical Trial of DP-R206 and Bonvia In Postmenopausal Women With Osteoporosis","status":"COMPLETED","sponsor":"Alvogen Korea","startDate":"2011-12","conditions":"Postmenopausal Women With Osteoporosis","enrollment":201},{"nctId":"NCT01577849","phase":"PHASE1","title":"Safety and Pharmacokinetic Characteristics of DP-R206(Vitamin D3) in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"Alvogen Korea","startDate":"2012-03","conditions":"Healthy","enrollment":36},{"nctId":"NCT02948881","phase":"PHASE4","title":"A Study To Assess The Quality Of Bone In Patients Taking Oral Ibandronate Versus Placebo","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-08","conditions":"Osteoporosis","enrollment":100},{"nctId":"NCT00545779","phase":"PHASE3","title":"BONCURE Study: A Study of Monthly Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis on Bisphosphonate Therapy.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2006-12","conditions":"Post-Menopausal Osteoporosis","enrollment":677},{"nctId":"NCT00545363","phase":"PHASE4","title":"A Study of Adherence to Once Monthly Ibandronate (Bonviva) in Women With Post-Menopausal Osteoporosis, Supported by a Patient Relationship Program (PRP)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2006-04","conditions":"Postmenopausal Osteoporosis","enrollment":716},{"nctId":"NCT00377234","phase":"PHASE4","title":"A Study Comparing Monthly Boniva (Ibandronate) and Weekly Risedronate in Women With Post-Menopausal Osteoporosis.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2006-05","conditions":"Post Menopausal Osteoporosis","enrollment":356},{"nctId":"NCT02739594","phase":"PHASE3","title":"Comparison of Ibandronate - Zoledronate Regarding Nephrotoxicity in Multiple Myeloma","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2006-02","conditions":"Multiple Myeloma","enrollment":89},{"nctId":"NCT00545051","phase":"PHASE4","title":"A Study of Once Monthly Bonviva (Ibandronate) in Prevention of Glucocorticoid-Induced Osteoporosis.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2006-05","conditions":"Postmenopausal Osteoporosis","enrollment":140},{"nctId":"NCT00303485","phase":"PHASE4","title":"A Study of Bone Turnover Markers in Post-Menopausal Women With Osteoporosis Treated With Monthly Boniva (Ibandronate)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2006-02","conditions":"Post Menopausal Osteoporosis","enrollment":67},{"nctId":"NCT02716792","phase":"PHASE3","title":"A Study to Evaluate Renal Safety of Intravenous Ibandronate (Bondronat) in Participants With Metastatic Bone Disease Due to Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2006-01","conditions":"Pain; Bone Neoplasms; Neoplasm Metastasis","enrollment":334},{"nctId":"NCT02598934","phase":"PHASE4","title":"A Study of Ibandronate (Boniva) to Evaluate Bone Turnover Markers in Women With Treatment-Naive Postmenopausal Osteoporosis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2004-08","conditions":"Post Menopausal Osteoporosis","enrollment":308},{"nctId":"NCT00493623","phase":"PHASE3","title":"BONDIR Study: A Study of Intravenous Bonviva (Ibandronate) After Recent Vertebral Osteoporotic Fracture in Patients With Osteoporosis.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2007-06","conditions":"Osteoporosis","enrollment":68},{"nctId":"NCT00492843","phase":"PHASE4","title":"Loading Dose or Standard Dose of Intravenous Ibandronate in Treating Patients With Lung Cancer and Skeletal Metastasis","status":"TERMINATED","sponsor":"Chinese Society of Lung Cancer","startDate":"2007-07","conditions":"Lung Cancer","enrollment":20},{"nctId":"NCT00048074","phase":"PHASE3","title":"DIVA Study - A Study of Different Regimens of Intravenous Administration of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2002-06","conditions":"Post Menopausal Osteoporosis","enrollment":1395},{"nctId":"NCT00129623","phase":"PHASE4","title":"A Study of Bonviva (Ibandronate) Once Monthly in Post-Menopausal Women With Osteopenia","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2005-12","conditions":"Post-Menopausal Osteopenia","enrollment":160},{"nctId":"NCT02553707","phase":"PHASE4","title":"A Study to Assess the Short Term Efficacy of Intravenous Ibandronate (Bondronat) in Participants With Metastatic Bone Pain Due to Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2006-07","conditions":"Pain; Bone Neoplasms; Neoplasm Metastasis","enrollment":182},{"nctId":"NCT00532220","phase":"PHASE3","title":"Study Into the Effect of Ibandronate for the Treatment of Bone Marrow Edema in Relation to Spontaneous or Non-traumatic Osteonecrosis of the Knee: A Randomized Double-blind, Placebo-controlled Trial","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2007-12","conditions":"Osteonecrosis of the Knee, Bone Marrow Edema of the Knee","enrollment":30},{"nctId":"NCT02528747","phase":"","title":"A Survey of Breast Cancer Patients With Metastatic Bone Disease Receiving Oral Ibandronate","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-01","conditions":"Metastatic Breast Cancer","enrollment":582},{"nctId":"NCT00545480","phase":"PHASE4","title":"SUMMIT Study: A Study of Persistence to Bonviva (Ibandronate) Once Monthly in Women With Post-Menopausal Osteoporosis.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2006-07","conditions":"Post Menopausal Osteoporosis","enrollment":596},{"nctId":"NCT01290094","phase":"PHASE3","title":"A Study of Bonviva/Boniva (Ibandronate) in Biphosphonate-Naïve Women With Post-Menopausal Osteoporosis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-04","conditions":"Post Menopausal Osteoporosis","enrollment":41},{"nctId":"NCT01287533","phase":"PHASE4","title":"Efficacy of Monthly Ibandronate in Women With RA and Reduced Bone Mineral Density Receiving Long-term Steroids","status":"COMPLETED","sponsor":"Yeong-Wook Song","startDate":"2010-04","conditions":"Rheumatoid Arthritis, Osteoporosis, Osteopenia","enrollment":167},{"nctId":"NCT00446589","phase":"PHASE4","title":"The Effects of Ibandronate or Teriparatide Therapy on Bone Histology and Biochemical Indices in Patients on Hemodialysis With Low Bone Mineral Density","status":"TERMINATED","sponsor":"Papageorgiou General Hospital","startDate":"2006-07","conditions":"Osteoporosis","enrollment":19},{"nctId":"NCT02271204","phase":"","title":"Observational Study of iv Ibandronate in Women With Postmenopausal Osteoporosis","status":"COMPLETED","sponsor":"Clinic of Endocrinology and Metabolic Disorders, Macedonia","startDate":"2009-03","conditions":"Osteoporosis","enrollment":700},{"nctId":"NCT02249741","phase":"PHASE4","title":"Prospective Study of Profile of Hepatic Osteodystrophy in Patients With Non-Choleastatic Liver Cirrhosis and Impact of Bisphosphonate Supplementation","status":"COMPLETED","sponsor":"Dr. Ashish Kumar","startDate":"2012-08","conditions":"Cirrhosis","enrollment":47},{"nctId":"NCT00196859","phase":"PHASE3","title":"Study in Elderly Patients With Early Breast Cancer (ICE)","status":"COMPLETED","sponsor":"GBG Forschungs GmbH","startDate":"2004-06","conditions":"Breast Cancer","enrollment":1500},{"nctId":"NCT00196872","phase":"PHASE3","title":"A Study to Compare ETC vs. EC-TX and Ibandronate vs. Observation in Patients With Node-positive Primary Breast Cancer (GAIN)","status":"COMPLETED","sponsor":"GBG Forschungs GmbH","startDate":"2004-07","conditions":"Breast Cancer","enrollment":3000},{"nctId":"NCT01376102","phase":"","title":"BONVIVA(Ibandronate) Injection PMS(Post-marketing Surveillance)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-11","conditions":"Osteoporosis","enrollment":657},{"nctId":"NCT00091832","phase":"PHASE2","title":"Denosumab (AMG 162) in Bisphosphonate Naive Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Amgen","startDate":"2004-09","conditions":"Breast Cancer, Metastases, Bone Metastases in Subjects With Advanced Breast Cancer","enrollment":255},{"nctId":"NCT00502736","phase":"PHASE2","title":"A Study of Loading Doses of Intravenous Bondronat (Ibandronate) in Patients With Breast Cancer and Malignant Bone Disease.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-01","conditions":"Pain; Bone Neoplasms; Neoplasm Metastasis","enrollment":13},{"nctId":"NCT00767169","phase":"PHASE2","title":"Bisphosphonate-coated Dental Implants","status":"COMPLETED","sponsor":"University Hospital, Linkoeping","startDate":"2008-10","conditions":"Edentatio (Toothlessness)","enrollment":16},{"nctId":"NCT00301886","phase":"PHASE3","title":"S0308 Zoledronate or Ibandronate in Preventing Bone Problems in Women With Stage IV Breast Cancer That Has Spread to the Bone","status":"WITHDRAWN","sponsor":"SWOG Cancer Research Network","startDate":"2006-05","conditions":"Breast Cancer, Hypercalcemia of Malignancy, Metastatic Cancer","enrollment":""},{"nctId":"NCT00683163","phase":"PHASE2, PHASE3","title":"PTH & Ibandronate Combination Study (PICS)","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2008-05","conditions":"Osteoporosis","enrollment":44},{"nctId":"NCT00082927","phase":"PHASE3","title":"Single-Dose Local Radiation Therapy Compared With Ibandronate in Treating Patients With Localized Metastatic Bone Pain","status":"COMPLETED","sponsor":"Cancer Research UK","startDate":"2003-04","conditions":"Metastatic Cancer, Pain, Prostate Cancer","enrollment":580},{"nctId":"NCT00873808","phase":"","title":"S0307A, Long-Term Bone Quality in Women With Breast Cancer Enrolled on Clinical Trial SWOG-S0307","status":"WITHDRAWN","sponsor":"SWOG Cancer Research Network","startDate":"2008-10","conditions":"Breast Cancer","enrollment":""},{"nctId":"NCT00326820","phase":"PHASE3","title":"Ibandronate or Zoledronate in Treating Patients With Newly Diagnosed Bone Metastases From Breast Cancer","status":"UNKNOWN","sponsor":"Wales Cancer Trials Unit","startDate":"2006-01","conditions":"Breast Cancer, Hypercalcemia of Malignancy, Metastatic Cancer","enrollment":1404},{"nctId":"NCT00936897","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Denosumab and Ibandronate in Postmenopausal Women Sub-Optimally Treated With Daily or Weekly Bisphosphonates","status":"COMPLETED","sponsor":"Amgen","startDate":"2009-07","conditions":"Postmenopausal Osteoporosis","enrollment":833},{"nctId":"NCT01381393","phase":"","title":"BONVIVA(Ibandronate) PMS(Post-marketing Surveillance )","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-06","conditions":"Osteoporosis","enrollment":659},{"nctId":"NCT00447915","phase":"PHASE3","title":"Phase II/III Clinical Study of R484iv (Ibandronic Acid) for Primary Osteoporosis","status":"COMPLETED","sponsor":"Chugai Pharmaceutical","startDate":"2007-03","conditions":"Primary Osteoporosis","enrollment":1265},{"nctId":"NCT01627886","phase":"PHASE1","title":"Bioequivalence Study of Ibandronate Sodium Tablets 150 mg Under Fasting Condition","status":"COMPLETED","sponsor":"Dr. Reddy's Laboratories Limited","startDate":"2008-09","conditions":"Healthy","enrollment":100},{"nctId":"NCT00668330","phase":"PHASE4","title":"Steroid Induced Osteoporosis in Patients With Systemic Lupus Erythematosus","status":"COMPLETED","sponsor":"Chinese University of Hong Kong","startDate":"2007-04","conditions":"Systemic Lupus Erythematosus","enrollment":40},{"nctId":"NCT00551174","phase":"PHASE4","title":"A Study of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis Who Have Received Previous Bonviva Treatment","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2004-10","conditions":"Post-Menopausal Osteoporosis","enrollment":781},{"nctId":"NCT00503113","phase":"PHASE4","title":"A Study of Bonviva (Ibandronate) and Alendronate on Renal Function in Postmenopausal Women With Osteoporosis at High Risk for Renal Disease.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2007-07","conditions":"Post-Menopausal Osteoporosis","enrollment":801},{"nctId":"NCT00423384","phase":"PHASE2, PHASE3","title":"Ibandronate Versus Placebo in the Prevention of Bone Loss After Renal Transplantation.","status":"UNKNOWN","sponsor":"Smerud Medical Research International AS","startDate":"2007-01","conditions":"Renal Transplant","enrollment":130},{"nctId":"NCT00397839","phase":"PHASE3","title":"The Effect Of Oral Ibandronate In Male Osteoporosis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2007-01","conditions":"Male Osteoporosis","enrollment":135},{"nctId":"NCT00271713","phase":"PHASE4","title":"Impact of Oral Ibandronate 150 mg Monthly on Structural Properties of Bone in Postmenopausal Osteoporosis (SPIMOS-3D)","status":"COMPLETED","sponsor":"Charite University, Berlin, Germany","startDate":"2006-03","conditions":"Osteoporosis, Postmenopausal","enrollment":70},{"nctId":"NCT00381368","phase":"PHASE2","title":"Safety and Efficacy Study of Intravenous Loading Dose of Ibandronate in Breast Cancer Patients","status":"UNKNOWN","sponsor":"University of Turku","startDate":"2006-10","conditions":"Breast Cancer","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":9,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["no other names"],"phase":"marketed","status":"active","brandName":"Ibandronate (Bondronat)","genericName":"Ibandronate (Bondronat)","companyName":"Chinese Society of Lung Cancer","companyId":"chinese-society-of-lung-cancer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ibandronate is a bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite in bone and blocking farnesyl pyrophosphate synthase in the mevalonate pathway. Used for Bone metastases in breast cancer, Osteoporosis prevention and treatment, Hypercalcemia of malignancy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}